Jeff York Email Address

Principal Human Resources Consultant

Seres Therapeutics, Inc. is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the natural state of bacterial diversity and function is imbalanced. A Phase 2 study of Seres' program SER-109 has been completed in multiply recurrent Clostridium difficile infection. Seres' clinical candidate, SER-287, is being evaluated in a Phase 1b study in patients with mild-to-moderate ulcerative colitis (UC). Seres is also developing SER-262, the first ever synthetic microbiome therapeutic candidate, in a Phase 1b study in patients with primary CDI.

I get most excited by disruptive, first-in-class ideas, which is often a messy venture at best. . . and an exciting challenge. I have been fortunate to have opportunities where I could help lead significant change as companies evolved through IPO, M&A, divestitures, periods of high growth (and decline), from R&D to Commercial launch, and net loss up to $1B+ revenue. These companies collectively spanned from 30 to 30,000 employees, including several highlight years ranked among Fortune magazines "100 Best Companies to Work For." Most importantly, I love working with people who love what they do. Life is too short to wish you were somewhere else.